Drug intelligence / Profile preview

ExoCoVac

Development stage: Preclinical
Lead developer: Innovex Therapeutics
Modality: Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics

Overview

ExoCoVac is an exosome-based vaccine candidate being developed by Innovex Therapeutics for the prevention of COVID-19 (SARS-CoV-2). The vaccine utilizes a proprietary platform that leverages circulating extracellular vesicles (EVs) isolated from COVID-19 patients to present SARS-CoV-2 antigens. By utilizing these naturally occurring vesicles, the vaccine is designed to elicit a comprehensive immune response, including specific IgG antibodies and long-lived, non-exhausted effector memory T-cell responses. ExoCoVac is currently in the preclinical stage of development, with early-stage discovery work utilizing ACE2-chimeric humanized mouse models to evaluate its protective efficacy and immunogenicity.

Beyond the preview

Go deeper on ExoCoVac.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ExoCoVac.

Explore the full profile